GLA

Alpha-galactosidase A · P06280 · GLA on Sugi Atlas →

537,010 patent compounds predicted against GLA, 336,843 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL25184 SCHEMBL25184 0.63 7/20
Amiloride Amiloride (SCHEMBL27562) 0.52 7/20
SCHEMBL6627 SCHEMBL6627 0.54 6/20
Umbelliferone Umbelliferone (SCHEMBL22018) 1.00 5/20
Duvoglustat Duvoglustat (SCHEMBL2969) 1.00 4/20
Terazosin Terazosin (SCHEMBL6528) 1.00 4/20
Prazosin Prazosin (SCHEMBL26524) 1.00 4/20
SCHEMBL31015 SCHEMBL31015 0.61 4/20
SCHEMBL23981 SCHEMBL23981 0.46 4/20
Esculin Esculin (SCHEMBL2893) 1.00 3/20
Esculin Esculin (SCHEMBL2894) 1.00 3/20
Camptothecin Camptothecin (SCHEMBL6038) 1.00 3/20
Hymecromone Hymecromone (SCHEMBL24150) 1.00 3/20
Esculetin Esculetin (SCHEMBL24641) 1.00 3/20
Amiloride Amiloride (SCHEMBL27563) 1.00 3/20
Hymecromone Hymecromone (SCHEMBL31014) 0.96 3/20
9-Aminocamptothecin 9-Aminocamptothecin (SCHEMBL26578) 0.82 3/20
Hydroxycamptothecin Hydroxycamptothecin (SCHEMBL25875) 0.80 3/20
Rubitecan Rubitecan (SCHEMBL8640) 0.78 3/20
Iodide Iodide (SCHEMBL14996) 0.65 3/20

Clinical trials — most relevant to GLA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta PHASE4COMPLETED
Efficacy and Tolerability of α-galactosidase in Treating Gas-related Symptoms in Children PHASE4COMPLETED
Switch Over Study of Biosimilar Agalsidase Beta for Fabry Disease PHASE3COMPLETED
Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease PHASE3RECRUITING
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease PHASE3COMPLETED
A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease PHASE2COMPLETED
Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease PHASE1/PHASE2WITHDRAWN
A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease PHASE2COMPLETED
A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease PHASE2COMPLETED
Safety and Efficacy of Gabapentin for Neuropathic Pain in Fabry Disease PHASE2WITHDRAWN
Autologous Stem Cell Transplantation of Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease PHASE1COMPLETED
Biomarker for Patients With Fabry Disease (BioFabry) nanWITHDRAWN
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy nanUNKNOWN
Taiwan Registry of Hypertrophic Cardiomyopathy (THIC) Research Synopsis nanRECRUITING
Evaluation of Phenotypic Variability in Fabry Disease nanWITHDRAWN
Screening of Fabry Disease in Patients With GI Symptoms nanUNKNOWN
Myocardial Affectation in Patients With Fabry Disease Without Phenotypic Manifestation. Diagnostic Value of Biomarkers nanUNKNOWN
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease nanRECRUITING
Assess Urine Biomarkers to Predict Nephropathy in Fabry Disease nanUNKNOWN
Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity nanCOMPLETED
Effect of Migalastat on Cardiac Involvement in Fabry Disease nanCOMPLETED
Early Detection and Follow-Up of Patients With Fabry's Disease nanUNKNOWN
Quality of Life in Adults With Untreated Fabry Disease in Sweden (QoLUF) nanNOT_YET_RECRUITING
Fabry Aim Children Early (ACE) Project nanWITHDRAWN
Alpha-galactosidase Enzyme and Irritable Bowel Syndrome nanUNKNOWN
Registry Gangliosidoses nanUNKNOWN
A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease nanCOMPLETED
A Study of Patients With Fabry Disease (US Specific) nanRECRUITING
Observational Study on Long-term Use of Pegunigalsidase Alfa in Fabry Patients in a Real-world Setting nanNOT_YET_RECRUITING
Natural History in Fabry Patients With IVS4+919G>A Mutation nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a GLA binder may also engage these)

ProteinNameSimilarity
P51569 1.000 P51569 →
Q58DH9 1.000 Q58DH9 →
Q9QWR8 1.000 Q9QWR8 →
Q90744 0.994 Q90744 →
P17050 0.993 P17050 →
P14749 0.991 P14749 →
Q66H12 0.991 Q66H12 →
Q9FT97 0.991 Q9FT97 →
Q8RX86 0.989 Q8RX86 →
Q0CPK2 0.987 Q0CPK2 →
Q8VC60 0.987 Q8VC60 →
Q8VXZ7 0.987 Q8VXZ7 →
Q9VTJ4 0.987 Q9VTJ4 →
Q2KIM0 0.986 Q2KIM0 →
P17164 0.986 P17164 →
Q9FXT4 0.986 Q9FXT4 →
Q5R7P4 0.986 Q5R7P4 →
Q60HF8 0.985 Q60HF8 →
Q60HF6 0.984 Q60HF6 →
Q58D55 0.984 Q58D55 →
P41947 0.984 P41947 →
Q99LJ1 0.984 Q99LJ1 →
Q9UVD6 0.984 Q9UVD6 →
GLB1 Beta-galactosidase 0.983 landscape →
P48300 0.983 P48300 →
P23780 0.983 P23780 →
P31428 0.983 P31428 →
Q2VQV9 0.983 Q2VQV9 →
P70699 0.982 P70699 →
Q9TRY9 0.982 Q9TRY9 →